Phase 3b RCT in 451 adults with active psoriatic arthritis after one TNF inhibitor: ACR20 at week 24 was 58.6% with guselkumab every 4 weeks and 62.2% every 8 weeks vs 34.8% with placebo; adverse events 46.7%, 53.6% and 48.3%.
RCTn = 451
Ogdie et al. Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of a Phase 3, Randomized, Placebo-Controlled Study